NSCLC IO 2022 - Midyear Review

Transcriptional signatures of COPII vesicle and Golgi targeting were identified as potential novel response biomarkers to vidutolimod, a first-in-class CpG-A TLR9 agonist, in combination anti–PD-L1-targeted therapy. Read More ›

Analysis of circulating tumor DNA can identify patients at high risk of early disease progression who could benefit from combining immune checkpoint inhibitors with chemotherapy. Read More ›

A highly multiplexed proteomic assay was developed to guide treatment selection for patients with lung cancer. Read More ›

Implementing a machine learning–based system that integrates radiologic, pathologic, and genomic data to predict response to PD-1 blockade may be able to outperform conventional unimodal approaches. Read More ›

Administering nivolumab in the morning improved progression-free survival and overall survival compared with administration during later times of the day, suggesting that circadian rhythm may affect its efficacy. Read More ›

Mechanisms of acquired resistance to anti–PD-(L)1 therapy in patients with advanced NSCLC are heterogeneous and require novel therapeutic strategies to be surmounted. Read More ›

Patients with NSCLC with poor performance status (PS) had significantly worse survival outcomes and were more likely to utilize healthcare services than those with favorable PS. Read More ›

A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade. Read More ›

In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes. Read More ›

Mutations in the ATM gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy. Read More ›

Page 1 of 3

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications